Hyoty H, Kaariainen S, Laiho JE, Comer GM, et al. Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial. Diabetologia 2024 Feb 19. doi: 10.1007/s00125-024-06092.
PMID: 38369573